RVNC
Revance Therapeutics Inc
Price:  
3.65 
USD
Volume:  
4,122,600.00
United States | Pharmaceuticals
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

RVNC EV/EBITDA

-693.1%
Upside

As of 2025-07-07, the EV/EBITDA ratio of Revance Therapeutics Inc (RVNC) is -4.67. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RVNC's latest enterprise value is 764.47 mil USD. RVNC's TTM EBITDA according to its financial statements is -163.87 mil USD. Dividing these 2 quantities gives us the above RVNC EV/EBITDA ratio.

Note: valuation result may not be accurate due to the company's negative EBITDA.

Range Selected
Trailing P/E multiples 7.1x - 10.3x 8.1x
Forward P/E multiples 11.1x - 17.7x 14.8x
Fair Price (21.13) - (19.81) (21.65)
Upside -678.9% - -642.8% -693.1%
3.65 USD
Stock Price
(21.65) USD
Fair Price

RVNC EV/EBITDA - Historical EV/EBITDA Data

Date EV/EBITDA